jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Ankle tissue - Medium Biopsy 1-3 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Medium biopsy from ankle lesion.

₹370₹529

30% OFF

Ankle Tissue - Medium Biopsy 1-3 cm

  • Why is it done?
    • Diagnose skin conditions and lesions located on the ankle region, including suspicious pigmented lesions, nodules, ulcers, or dermatological abnormalities
    • Evaluate for malignant melanoma, basal cell carcinoma, squamous cell carcinoma, and other skin malignancies
    • Obtain tissue samples for histopathological examination when clinical examination alone cannot definitively establish a diagnosis
    • Assess inflammatory, infectious, or systemic conditions affecting ankle skin and subcutaneous tissues
    • Determine depth of lesion invasion and margins for surgical planning
    • Typically performed when lesions are suspicious for malignancy, persist despite treatment, or show concerning features on dermatological examination
  • Normal Range
    • Normal Result: Benign tissue with no malignancy; histology shows normal skin architecture without atypical cells, dysplasia, or suspicious features
    • Specimen Size: 1-3 cm tissue sample collected via excisional, punch, or incisional biopsy technique
    • Negative for Malignancy: Absence of cancer cells; tissue is processed for histological examination and may be stained with H&E (Hematoxylin & Eosin) stain
    • Negative for Dysplasia: No evidence of cellular abnormalities or pre-malignant changes
    • Special Studies: May include immunohistochemistry (IHC), melanoma markers (S-100, Melan-A, SOX10), or genetic testing if indicated
    • Interpretation: Results classified as benign, atypical/dysplastic, or malignant based on microscopic examination by pathologist
  • Interpretation
    • Benign Findings: No malignancy detected; may include common nevi, seborrheic keratosis, hemangioma, lipoma, or inflammatory conditions; reassurance provided
    • Atypical/Dysplastic Results: Cells show abnormal features but not diagnostic of malignancy; may indicate dysplastic nevus, actinic keratosis, or borderline lesion; requires close clinical follow-up and possible re-excision
    • Malignant Findings: Cancer cells identified; specific type documented (melanoma, basal cell carcinoma, squamous cell carcinoma, etc.); stage and grade assessed; immediate treatment planning required
    • Tumor Characteristics Assessed: Breslow thickness (for melanoma), Clark level, mitotic rate, ulceration, margins, lymphovascular invasion
    • Margin Status: Clear margins indicate complete lesion removal; involved or close margins may necessitate re-excision for adequate tumor control
    • Factors Affecting Results: Sample adequacy, tissue fixation quality, staining technique, pathologist expertise, sun exposure history, genetic predisposition, immunosuppression status
    • Clinical Significance: Results guide treatment decisions, determine prognosis, identify need for additional imaging or sentinel lymph node biopsy, and establish follow-up surveillance protocols
  • Associated Organs
    • Primary Organ System: Integumentary system (skin); subcutaneous tissues; lower extremity musculoskeletal structures
    • Conditions Associated with Abnormal Results: Cutaneous melanoma, basal cell carcinoma, squamous cell carcinoma, dermatofibrosarcoma protuberans, Merkel cell carcinoma, lymphoma, inflammatory conditions (sarcoidosis, granulomatous infections)
    • Complications and Risks: Bleeding, infection, scarring, keloid formation, nerve damage, unsatisfactory cosmetic outcome; malignant findings may lead to extensive surgical resection, chemotherapy, immunotherapy, or radiation therapy
    • Systemic Implications: Cutaneous malignancy may indicate risk for metastatic disease; melanoma can spread to lymph nodes, lungs, brain, liver, and bones; requires oncological staging and systemic evaluation
    • Lymphatic Involvement: Regional lymph nodes draining ankle area (popliteal, inguinal) may be affected; sentinel lymph node biopsy may be indicated for melanoma
  • Follow-up Tests
    • If Malignancy Confirmed: Sentinel lymph node biopsy, full-body skin examination, imaging studies (CT chest/abdomen/pelvis, MRI), positron emission tomography (PET) scan for staging
    • Molecular/Genetic Testing: BRAF V600E mutation testing, NRAS mutation analysis, KIT mutation testing for melanoma prognostic and therapeutic guidance; immunohistochemistry for PD-L1, microsatellite instability (MSI)
    • Dermatology Follow-up: Clinical surveillance with dermatoscopy every 3-6 months for benign findings; total body photography to monitor for new lesions
    • Oncology Consultation: Immediate referral for malignant findings; treatment planning may include surgical re-excision, wide local excision, immunotherapy, targeted therapy, or chemotherapy
    • Lymph Node Imaging: Ultrasound of inguinal/popliteal lymph nodes, CT or MRI for regional nodal staging
    • Laboratory Tests: Serum LDH (lactate dehydrogenase), complete blood count, comprehensive metabolic panel; blood-based tumor markers if applicable
    • For Atypical/Dysplastic Results: Re-excision with wider margins, repeat biopsy if margins involved, enhanced dermatological surveillance with shorter intervals
    • Monitoring Frequency: Stage I-II melanoma: every 3-6 months for 2-3 years, then annual surveillance; Stage III-IV: more frequent imaging and clinical assessment as per oncology protocols
  • Fasting Required?
    • Fasting: No
    • Pre-procedure Instructions: Patient may eat and drink normally; no fasting period required as this is a localized skin biopsy procedure
    • Medications to Avoid: Discontinue aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) 5-7 days prior if possible to reduce bleeding risk; consult with physician regarding warfarin, clopidogrel, or other anticoagulants; do not stop prescribed anticoagulation without medical approval
    • Skin Preparation: Cleanse biopsy site gently with mild soap and water morning of procedure; do not apply lotions, makeup, or sunscreen to area; wear clean, loose-fitting clothing
    • Anesthesia: Local anesthesia used; no need for general anesthesia; procedure can be performed in outpatient office setting
    • Appointment Timing: Can be scheduled at any time of day; allow 15-30 minutes for procedure; no recovery time needed beyond brief observation
    • Post-procedure Care: Keep biopsy site clean and dry; apply antibiotic ointment as directed; avoid strenuous activity and excessive ankle movement for 24-48 hours; keep wound covered if needed; watch for signs of infection (increasing redness, warmth, pus, fever)
    • Wound Dressing: Pressure dressing applied immediately after biopsy; may be removed after 24 hours; sutures may be placed depending on technique and wound size
    • Results Timeline: Histopathology results typically available within 5-10 business days; complex cases with special stains or immunohistochemistry may take 10-14 days

How our test process works!

customers
customers